logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Percutaneous Coronary Intervention

    Medications for Percutaneous Coronary Intervention

    FiltersReset Filters
    11 results

    • argatroban

      (Argatroban)
      Par Pharmaceutical, Inc.
      Usage: Argatroban Injection is indicated for the prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT), and as an anticoagulant in those with or at risk for HIT undergoing percutaneous coronary intervention (PCI).

    • argatroban

      (Argatroban)
      Par Pharmaceutical, Inc.
      Usage: Argatroban Injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant during percutaneous coronary interventions (PCI) in patients with or at risk for HIT.

    • argatroban

      (Argatroban)
      Gland Pharma Limited
      Usage: Argatroban Injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant for those with or at risk for HIT undergoing percutaneous coronary intervention (PCI).

    • argatroban

      (Argatroban)
      Amneal Pharmaceuticals LLC
      Usage: Argatroban injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant in patients with HIT undergoing percutaneous coronary intervention (PCI).

    • argatroban

      (Argatroban)
      Hikma Pharmaceuticals USA Inc.
      Usage: Argatroban Injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant for those undergoing percutaneous coronary intervention (PCI) who are at risk for HIT.

    • bivalirudin

      (bivalirudin)
      Accord Healthcare, Inc.
      Usage: Bivalirudin for injection is indicated as an anticoagulant for patients undergoing percutaneous coronary intervention (PCI), including those with heparin-induced thrombocytopenia and thrombosis syndrome.

    • eptifibatide

      (eptifibatide)
      Slate Run Pharmaceuticals, LLC
      Usage: Eptifibatide injection is indicated for reducing the risk of death or myocardial infarction in patients with acute coronary syndrome and for decreasing adverse outcomes during percutaneous coronary intervention, including those requiring intracoronary stenting.

    • eptifibatide

      (Eptifibatide)
      Hainan Shuangcheng Pharmaceuticals Co., Ltd.
      Usage: Eptifibatide injection is indicated to reduce the risk of death or new myocardial infarction in patients with acute coronary syndrome (ACS) and to decrease the rate of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), including those receiving intracoronary stenting.

    • eptifibatide

      (eptifibatide)
      Sagent Pharmaceuticals
      Usage: Eptifibatide Injection is indicated for the management of Acute Coronary Syndrome (ACS) to reduce the risk of death or new myocardial infarction. It is also used during Percutaneous Coronary Intervention (PCI) to lower the rates of death, new MI, or the need for urgent intervention.

    • eptifibatide

      (eptifibatide)
      Mylan Institutional LLC
      Usage: Eptifibatide injection is indicated for reducing the risk of death or new myocardial infarction in patients with acute coronary syndrome (ACS) and for decreasing complications in patients undergoing percutaneous coronary intervention (PCI), including those receiving intracoronary stenting.